Artisan Partners Limited Partnership lessened its position in shares of Veracyte, Inc. (NASDAQ:VCYT – Get Rating) by 14.8% during the 2nd quarter, Holdings Channel reports. The firm owned 3,841,439 shares of the biotechnology company’s stock after selling 664,908 shares during the quarter. Artisan Partners Limited Partnership owned about 0.05% of Veracyte worth $76,445,000 as of its most recent filing with the SEC.
Several other institutional investors have also recently modified their holdings of the company. Point72 Hong Kong Ltd acquired a new stake in shares of Veracyte in the first quarter worth $33,000. Assetmark Inc. lifted its stake in shares of Veracyte by 90.3% in the 2nd quarter. Assetmark Inc. now owns 2,596 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 1,232 shares during the period. First Horizon Advisors Inc. boosted its holdings in Veracyte by 16,813.6% during the second quarter. First Horizon Advisors Inc. now owns 3,721 shares of the biotechnology company’s stock worth $73,000 after buying an additional 3,699 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Veracyte during the first quarter valued at $73,000. Finally, Lazard Asset Management LLC grew its position in shares of Veracyte by 27.4% during the 2nd quarter. Lazard Asset Management LLC now owns 4,346 shares of the biotechnology company’s stock valued at $86,000 after acquiring an additional 936 shares during the period.
Analysts Set New Price Targets
VCYT has been the topic of a number of recent analyst reports. Morgan Stanley lowered their price target on Veracyte from $23.00 to $22.00 and set an “underweight” rating on the stock in a research report on Friday, November 4th. Raymond James cut their price objective on Veracyte from $31.00 to $27.00 and set an “outperform” rating for the company in a research note on Friday, November 4th. SVB Leerink raised their target price on Veracyte from $30.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday, November 3rd. William Blair reiterated an “outperform” rating on shares of Veracyte in a research report on Wednesday, November 2nd. Finally, StockNews.com raised Veracyte from a “sell” rating to a “hold” rating in a research note on Friday, November 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $35.17.
Veracyte Trading Up 0.2 %
Insider Buying and Selling
In other news, insider Giulia C. Kennedy sold 1,023 shares of the firm’s stock in a transaction on Friday, November 4th. The stock was sold at an average price of $25.00, for a total transaction of $25,575.00. Following the completion of the transaction, the insider now directly owns 68,001 shares in the company, valued at $1,700,025. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, insider Giulia C. Kennedy sold 1,023 shares of the firm’s stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $25.00, for a total value of $25,575.00. Following the sale, the insider now owns 68,001 shares of the company’s stock, valued at $1,700,025. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Evan/ Fa Jones sold 6,000 shares of Veracyte stock in a transaction that occurred on Friday, November 11th. The stock was sold at an average price of $30.23, for a total transaction of $181,380.00. Following the completion of the transaction, the director now owns 52,451 shares of the company’s stock, valued at approximately $1,585,593.73. The disclosure for this sale can be found here. In the last quarter, insiders sold 7,025 shares of company stock valued at $207,014. Company insiders own 2.90% of the company’s stock.
Veracyte Company Profile
Veracyte, Inc operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis.
- Get a free copy of the StockNews.com research report on Veracyte (VCYT)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.